<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871351</url>
  </required_header>
  <id_info>
    <org_study_id>P06027</org_study_id>
    <nct_id>NCT00871351</nct_id>
  </id_info>
  <brief_title>Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)</brief_title>
  <official_title>Ezetimibe Phase IV Clinical Study in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and
      ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose
      low-density lipoprotein (LDL)-cholesterol levels have not reached the lipid management target
      value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or
      changing to rosuvastatin 2.5 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2009</start_date>
  <completion_date type="Actual">May 1, 2010</completion_date>
  <primary_completion_date type="Actual">May 1, 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values</measure>
    <time_frame>End of Week 4 to Week 16 or discontinuation</time_frame>
    <description>LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in LDL-C</measure>
    <time_frame>End of washout period to Week 16 or discontinuation</time_frame>
    <description>LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values</measure>
    <time_frame>Week 16 or discontinuation</time_frame>
    <description>LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation).
Target values:
For participants with history of coronary artery disease: &lt;100 mg/dL;
for participants with at least 3 cardiovascular (CV) risk factors: &lt;120 mg/dL;
for participants with 1-2 CV risk factors: &lt;140 mg/dL;
for participants with no CV risk factors: &lt;160 mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)</measure>
    <time_frame>End of Week 4 to Week 16 or discontinuation</time_frame>
    <description>Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lipids and Hs-CRP</measure>
    <time_frame>End of washout to Week 16 or discontinuation</time_frame>
    <description>Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)</description>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
    <other_name>SCH 058235</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)</description>
    <arm_group_label>Ezetimibe + Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week
             washout and low density lipoprotein-cholesterol (LDL-C) levels that had not reached
             the following lipid management target values during treatment: Category I (low-risk
             group) with no other risk factors - LDL-C &lt;160 mg/dL; Category II (mid-risk group)
             with 1-2 risk factors other than LDL-C levels - LDL-C &lt;140 mg/dL; Category III
             (high-risk group) with 3 or more other risk factors - LDL-C &lt;120 mg/dL; and for
             participants with history of coronary artery disease - LDL-C &lt;100 mg/dL.

          -  outpatient men or women, age 20 years and older

        Exclusion Criteria:

          -  fasted triglyceride level at the start of washout or treatment period exceeding 400
             mg/dL.

          -  homozygous familial hypercholesterolemia.

          -  creatine phosphokinase (CPK) &gt;2 times the upper limit of normal (X ULN) at start of
             washout or treatment period.

          -  glycosylated hemoglobin (HbA1c) &gt;=8ï¼… at start of washout or treatment period.

          -  severe hepatic function disorder, or aspartate aminotransferase (AST) or alanine
             aminotransferase (ALT) &gt;2X ULN at start of washout or treatment period.

          -  hypersensitivity to ezetimibe, atorvastatin, or rosuvastatin tablets.

          -  pregnant or lactating

          -  discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment
             period (however, if participant had taken atorvastatin 10 mg before the test conducted
             at the start of the observation period, a period of discontinuation of 27 days is
             allowed.)

          -  cyclosporine treatment

          -  hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary
             disease, chronic renal failure, and/or pancreatitis.

          -  hyperlipidemia associated with drug administration that causes adverse serum lipid
             effects.

          -  participation in a clinical study within 4 weeks of washout

          -  cancer or cancer history within previous 5 years, except for successfully treated
             basal cell carcinoma of the skin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <results_reference>
    <citation>Teramoto T, Sawada T, Iwamoto K, Daida H. Clinical Efficacy and Tolerability of Ezetimibe in Combination With Atorvastatin in Japanese Patients With Hypercholesterolemia-Ezetimibe Phase IV Randomized Controlled Trial in Patients With Hypercholesterolemia. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):16-40. doi: 10.1016/j.curtheres.2012.02.002.</citation>
    <PMID>24653510</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <results_first_submitted>May 16, 2011</results_first_submitted>
  <results_first_submitted_qc>July 26, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2011</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe + Atorvastatin</title>
          <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin</title>
          <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="P3">
          <title>Rosuvastatin</title>
          <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe + Atorvastatin</title>
          <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin</title>
          <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="B3">
          <title>Rosuvastatin</title>
          <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="11.4"/>
                    <measurement group_id="B2" value="59.3" spread="11.8"/>
                    <measurement group_id="B3" value="61.1" spread="12.0"/>
                    <measurement group_id="B4" value="61.0" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values</title>
        <description>LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).</description>
        <time_frame>End of Week 4 to Week 16 or discontinuation</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe + Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values</title>
          <description>LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).</description>
          <population>Randomized participants</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" lower_limit="-29.2" upper_limit="-22.4"/>
                    <measurement group_id="O2" value="-15.1" lower_limit="-18.6" upper_limit="-11.7"/>
                    <measurement group_id="O3" value="0.8" lower_limit="-3.3" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hochberg's method</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.4</ci_lower_limit>
            <ci_upper_limit>-5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hochberg's method</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-26.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.8</ci_lower_limit>
            <ci_upper_limit>-21.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in LDL-C</title>
        <description>LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).</description>
        <time_frame>End of washout period to Week 16 or discontinuation</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe + Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in LDL-C</title>
          <description>LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).</description>
          <population>Randomized participants</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.6" lower_limit="-52.9" upper_limit="-46.4"/>
                    <measurement group_id="O2" value="-41.1" lower_limit="-44.4" upper_limit="-37.9"/>
                    <measurement group_id="O3" value="-30.5" lower_limit="-34.4" upper_limit="-26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Hochberg's method</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Hochberg's method</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values</title>
        <description>LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation).
Target values:
For participants with history of coronary artery disease: &lt;100 mg/dL;
for participants with at least 3 cardiovascular (CV) risk factors: &lt;120 mg/dL;
for participants with 1-2 CV risk factors: &lt;140 mg/dL;
for participants with no CV risk factors: &lt;160 mg/dL.</description>
        <time_frame>Week 16 or discontinuation</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe + Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values</title>
          <description>LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation).
Target values:
For participants with history of coronary artery disease: &lt;100 mg/dL;
for participants with at least 3 cardiovascular (CV) risk factors: &lt;120 mg/dL;
for participants with 1-2 CV risk factors: &lt;140 mg/dL;
for participants with no CV risk factors: &lt;160 mg/dL.</description>
          <population>Randomized participants</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)</title>
        <description>Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.</description>
        <time_frame>End of Week 4 to Week 16 or discontinuation</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe + Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)</title>
          <description>Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.</description>
          <population>Randomized participants</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.0" lower_limit="-20.7" upper_limit="-15.2"/>
                    <measurement group_id="O2" value="-10.3" lower_limit="-13.1" upper_limit="-7.4"/>
                    <measurement group_id="O3" value="1.9" lower_limit="-1.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-14.4" upper_limit="12.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-10.9" upper_limit="11.4"/>
                    <measurement group_id="O3" value="14.7" lower_limit="2.3" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-Density Lipoprotein Cholesterol (HDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.9" upper_limit="8.2"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-2.6" upper_limit="3.5"/>
                    <measurement group_id="O3" value="2.5" lower_limit="-1.4" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.0" lower_limit="-28.5" upper_limit="-21.5"/>
                    <measurement group_id="O2" value="-13.7" lower_limit="-17.0" upper_limit="-10.3"/>
                    <measurement group_id="O3" value="2.0" lower_limit="-2.6" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sensitivity C-Reactive Protein (Hs-CRP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.0" lower_limit="-43.2" upper_limit="141.3"/>
                    <measurement group_id="O2" value="9.9" lower_limit="-24.1" upper_limit="43.9"/>
                    <measurement group_id="O3" value="25.7" lower_limit="-4.8" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Lipids and Hs-CRP</title>
        <description>Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).</description>
        <time_frame>End of washout to Week 16 or discontinuation</time_frame>
        <population>Randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe + Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Lipids and Hs-CRP</title>
          <description>Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).</description>
          <population>Randomized participants</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.9" lower_limit="-42.1" upper_limit="-37.7"/>
                    <measurement group_id="O2" value="-32.8" lower_limit="-35.8" upper_limit="-29.7"/>
                    <measurement group_id="O3" value="-24.4" lower_limit="-27.9" upper_limit="-21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.3" lower_limit="-36.0" upper_limit="-14.6"/>
                    <measurement group_id="O2" value="-18.8" lower_limit="-29.8" upper_limit="-7.8"/>
                    <measurement group_id="O3" value="-12.0" lower_limit="-21.3" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-Density Lipoprotein Cholesterol (HDL-C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="6.1" upper_limit="14.5"/>
                    <measurement group_id="O2" value="7.4" lower_limit="3.7" upper_limit="11.0"/>
                    <measurement group_id="O3" value="9.9" lower_limit="3.6" upper_limit="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.1" lower_limit="-52.7" upper_limit="-47.6"/>
                    <measurement group_id="O2" value="-41.4" lower_limit="-44.8" upper_limit="-37.9"/>
                    <measurement group_id="O3" value="-31.3" lower_limit="-35.4" upper_limit="-27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Sensitivity C-reactive Protein (Hs-CRP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="-84.4" upper_limit="230.4"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-36.3" upper_limit="30.4"/>
                    <measurement group_id="O3" value="-13.6" lower_limit="-39.7" upper_limit="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Randomized participants</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe + Atorvastatin</title>
          <description>Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin</title>
          <description>Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
        <group group_id="E3">
          <title>Rosuvastatin</title>
          <description>Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="47"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish/present any interim results of the study without Sponsor's prior written consent. The investigator further agrees to provide to the sponsor 45 days prior to submission, review copies of abstracts/manuscripts that report any study results. The sponsor has the right to review and comment. If the parties disagree, investigator agrees to meet with the sponsor for the purpose of making good faith efforts to discuss and resolve any such issues or disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

